Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice

BackgroundProtease inhibitors (PI's) and reverse transcriptase drugs are important components of highly active antiretroviral therapy (HAART) for treating human acquired immunodeficiency syndrome (AIDS). Long-term clinical therapeutic efficacy and treatment compliance of these agents have been limited by undesirable side-effects, such as diarrhea. This study aims to investigate the effects of selected antiretroviral agents on intestinal histopathology and function in vivo and on cell proliferation and death in vitro.MethodsSelected antiretroviral drugs were given orally over 7 days, to Swiss mice, as follows: 100 mg/kg of nelfinavir (NFV), indinavir (IDV), didanosine (DDI) or 50 mg/kg of zidovudine (AZT). Intestinal permeability measured by lactulose and mannitol assays; net water and electrolyte transport, in perfused intestinal segments; and small intestinal morphology and cell apoptosis were assessed in treated and control mice. In vitro cell proliferation was evaluated using the WST-1 reagent and apoptosis and necrosis by flow cytometry analysis.ResultsNFV, IDV, AZT and DDI caused significant reductions in duodenal and in jejunal villus length (p < 0.05). IDV and AZT increased crypt depth in the duodenum and AZT increased crypt depth in the jejunum. NFV, AZT and DDI significantly decreased ileal crypt depth. All selected antiretroviral drugs significantly increased net water secretion and electrolyte secretion, except for DDI, which did not alter water or chloride secretion. Additionally, only NFV significantly increased mannitol and lactulose absorption. NFV and IDV caused a significant reduction in cell proliferation in vitro at both 24 h and 48 h. DDI and AZT did not alter cell proliferation. There was a significant increase in apoptosis rates in IEC-6 cells after 24 h with 70 ug/mL of NFV (control: 4.7% vs NFV: 22%) while IDV, AZT and DDI did not show any significant changes in apoptosis compared to the control group. In jejunal sections, IDV and NFV significantly increased the number of TUNEL positive cells.ConclusionThe PI's, NFV and IDV, increased cell apoptosis in vivo, water and electrolyte secretion and intestinal permeability and decreased villus length and cell proliferation. NFV was the only drug tested that increased cell apoptosis in vitro. The nucleoside reverse transcriptase inhibitors, AZT and DDI, did not affect cell apoptosis or proliferation. These findings may partly explain the intestinal side-effects associated with PI's.

[1]  S. Savkovic,et al.  Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation , 2003, Gut.

[2]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[3]  Huiping Zhou HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. , 2011, Methods in enzymology.

[4]  J. Fox,et al.  Direct analysis of mannitol, lactulose and glucose in urine samples by high-performance anion-exchange chromatography with pulse amperometric detection. Clinical evaluation of intestinal permeability in human immunodeficiency virus infection. , 1996, Journal of chromatography. B, Biomedical applications.

[5]  Min Guan,et al.  Anti-HIV drugs for cancer therapeutics: back to the future? , 2009, The Lancet. Oncology.

[6]  R. Guerrant,et al.  Cryptosporidial and microsporidial infections in human immunodeficiency virus-infected patients in northeastern Brazil. , 1994, The Journal of infectious diseases.

[7]  M. Zeitz,et al.  Enteric Immunologic Abnormalities in Human Immunodeficiency Virus Infection , 1992, Seminars in liver disease.

[8]  M. Montalto,et al.  Structure and function of tight junctions. Role in intestinal barrier. , 1999, Italian journal of gastroenterology and hepatology.

[9]  A. Nusrat,et al.  Regulation of the intestinal epithelial barrier by the apical junctional complex , 2006, Current opinion in gastroenterology.

[10]  D. Faulds,et al.  Nelfinavir. A review of its therapeutic efficacy in HIV infection. , 1998, Drugs.

[11]  H Cheng,et al.  Clonal analysis of mouse intestinal epithelial progenitors. , 1999, Gastroenterology.

[12]  A. Hill,et al.  Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. , 2009, AIDS reviews.

[13]  B. Fuchs,et al.  Stressing out over survival: glutamine as an apoptotic modulator. , 2006, The Journal of surgical research.

[14]  Roland Marquet,et al.  HIV-1 reverse transcriptase inhibitors , 2007, Applied Microbiology and Biotechnology.

[15]  R. Guerrant,et al.  Glutamine analogues as adjunctive therapy for infectious diarrhea , 2003, Current infectious disease reports.

[16]  A. Nusrat,et al.  Tight junctions and cell-cell interactions. , 2006, Methods in molecular biology.

[17]  Kerstin Bendfeldt,et al.  The HIV Protease Inhibitors Saquinavir, Ritonavir, and Nelfinavir Induce Apoptosis and Decrease Barrier Function in Human Intestinal Epithelial Cells , 2005, Antiviral therapy.

[18]  I. McGowan,et al.  Increased HIV-1 Mucosal Replication Is Associated With Generalized Mucosal Cytokine Activation , 2004, Journal of acquired immune deficiency syndromes.

[19]  B. Finlay,et al.  Attaching and effacing pathogen‐induced tight junction disruption in vivo , 2006, Cellular microbiology.

[20]  A. Lazzarin,et al.  Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. , 2007, The new microbiologica.

[21]  Robert H. Shoemaker,et al.  Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo , 2007, Clinical Cancer Research.

[22]  C. Potten,et al.  Stem cells in gastrointestinal epithelium: numbers, characteristics and death. , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  C. Flexner,et al.  Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. , 2004, American journal of physiology. Cell physiology.

[24]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death , 2005, Cell Death and Differentiation.

[25]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[26]  M. Zeitz,et al.  Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. , 1989, Annals of internal medicine.

[27]  R. Guerrant,et al.  Measurement of intestinal permeability using mannitol and lactulose in children with diarrheal diseases. , 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[28]  V. Subramanian,et al.  Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies , 2001, Mechanisms of Development.

[29]  R. Guerrant,et al.  Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil. , 1997, The American journal of gastroenterology.

[30]  P. Okhuysen,et al.  HIV1 and the gut in the era of highly active antiretroviral therapy , 2002, Current gastroenterology reports.

[31]  J. Ziegler,et al.  Tolerabilities of Antiretrovirals in Paediatric HIV Infection , 2002, Drug safety.

[32]  A. Guarino,et al.  Management of Gastrointestinal Disorders in Children with HIV Infection , 2004, Paediatric drugs.

[33]  E. Ribera,et al.  The future of antiretroviral therapy: challenges and needs. , 2010, The Journal of antimicrobial chemotherapy.

[34]  H. Schedl,et al.  Solute and Water Absorption by the Human Small Intestine , 1963, Nature.

[35]  K. Flaherty,et al.  HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. , 2007, Cancer research.

[36]  M. Postma,et al.  Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy , 2004, Quality of Life Research.

[37]  G. Plosker,et al.  Nelfinavir , 2000, Drugs.

[38]  S. Piscitelli,et al.  Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Mellors,et al.  Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and Prospects , 2009, Antiviral therapy.